Hyderabad Institute Of Urology Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 21 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.24 M
as on 24-10-2024
- Revenue 126.00%
(FY 2023)
- Profit 212.40%
(FY 2023)
- Ebitda -9.62%
(FY 2023)
- Net Worth 18.51%
(FY 2023)
- Total Assets 10.48%
(FY 2023)
About Hyderabad Institute Of Urology
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.24 M.
Venkata Kumar, Padmaja Aravabhumi, and Renuka Adipudi serve as directors at the Company.
- CIN/LLPIN
U85120TG2003PTC040422
- Company No.
040422
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hyderabad Institute Of Urology?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Kumar  | Director | 03-Feb-2003 | Current |
| Padmaja Aravabhumi | Director | 21-Apr-2011 | Current |
| Renuka Adipudi | Director | 21-Apr-2011 | Current |
Financial Performance and Corporate Structure Insights of Hyderabad Institute Of Urology.
Hyderabad Institute Of Urology Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 126% increase. The company also saw a substantial improvement in profitability, with a 212.4% increase in profit. The company's net worth Soared by an impressive increase of 18.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hyderabad Institute Of Urology?
In 2022, Hyderabad Institute Of Urology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hyderabad Lithotriplsy Centre Private LimitedActive 30 years 2 monthsVenkata Kumar and Padmaja Aravabhumi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 09 May 2011 | ₹0.84 M | Open |
Bank Of Baroda Creation Date: 28 Mar 2003 | ₹0.40 M | Open |
How Many Employees Work at Hyderabad Institute Of Urology?
Unlock and access historical data on people associated with Hyderabad Institute Of Urology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hyderabad Institute Of Urology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hyderabad Institute Of Urology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
